Caricamento...
Circulating exosomes express α(4)β(7) integrin and compete with CD4+ T cells for the binding to Vedolizumab
Vedolizumab (VDZ) is a therapeutic monoclonal antibody approved for the treatment of inflammatory bowel diseases (IBD). VDZ selectively binds to the α4β7 integrin and blocks trafficking of a specific subset of gastrointestinal-homing T-lymphocytes to inflamed tissue. Although VDZ has shown promising...
Salvato in:
| Pubblicato in: | PLoS One |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Public Library of Science
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7661055/ https://ncbi.nlm.nih.gov/pubmed/33180848 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0242342 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|